Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial FL Greenway, K Fujioka, RA Plodkowski, S Mudaliar, M Guttadauria, ... The Lancet 376 (9741), 595-605, 2010 | 994 | 2010 |
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II) CM Apovian, L Aronne, D Rubino, C Still, H Wyatt, C Burns, D Kim, ... Obesity 21 (5), 935-943, 2013 | 637 | 2013 |
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR‐BMOD trial TA Wadden, JP Foreyt, GD Foster, JO Hill, S Klein, PM O'neil, MG Perri, ... Obesity 19 (1), 110-120, 2011 | 554 | 2011 |
Rational design of a combination medication for the treatment of obesity FL Greenway, MJ Whitehouse, M Guttadauria, JW Anderson, RL Atkinson, ... Obesity 17 (1), 30-39, 2009 | 368 | 2009 |
The cost of treating anxiety: the medical and demographic correlates that impact total medical costs MD Marciniak, MJ Lage, E Dunayevich, JM Russell, L Bowman, ... Depression and anxiety 21 (4), 178-184, 2005 | 275 | 2005 |
Prevalence and description of psychotic features in bipolar mania E Dunayevich, PE Keck Jr Current psychiatry reports 2 (4), 286-290, 2000 | 240 | 2000 |
Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial I Miller, IE Scheffer, B Gunning, R Sanchez-Carpintero, A Gil-Nagel, ... JAMA neurology 77 (5), 613-621, 2020 | 212 | 2020 |
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder E Dunayevich, J Erickson, L Levine, R Landbloom, DD Schoepp, ... Neuropsychopharmacology 33 (7), 1603-1610, 2008 | 212 | 2008 |
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo FL Greenway, E Dunayevich, G Tollefson, J Erickson, M Guttadauria, ... The Journal of Clinical Endocrinology & Metabolism 94 (12), 4898-4906, 2009 | 206 | 2009 |
Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial J Hartford, S Kornstein, M Liebowitz, T Pigott, J Russell, M Detke, ... International Clinical Psychopharmacology 22 (3), 167-174, 2007 | 177 | 2007 |
Effort-based decision-making paradigms for clinical trials in schizophrenia: part 1—psychometric characteristics of 5 paradigms LF Reddy, WP Horan, DM Barch, RW Buchanan, E Dunayevich, JM Gold, ... Schizophrenia bulletin 41 (5), 1045-1054, 2015 | 175 | 2015 |
Medical and productivity costs of anxiety disorders: case control study M Marciniak, MJ Lage, RP Landbloom, E Dunayevich, L Bowman Depression and anxiety 19 (2), 112-120, 2004 | 174 | 2004 |
Twelve-month outcome in bipolar patients with and without personality disorders E Dunayevich, KW Sax, PE Keck Jr, SL McElroy, MT Sorter, ... Journal of Clinical Psychiatry 61 (2), 134-139, 2000 | 143 | 2000 |
Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians H Koponen, C Allgulander, J Erickson, E Dunayevich, Y Pritchett, ... Primary care companion to the Journal of clinical psychiatry 9 (2), 100, 2007 | 136 | 2007 |
Effort-based decision-making paradigms for clinical trials in schizophrenia: part 2—external validity and correlates WP Horan, LF Reddy, DM Barch, RW Buchanan, E Dunayevich, JM Gold, ... Schizophrenia bulletin 41 (5), 1055-1065, 2015 | 127 | 2015 |
Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder JA Mauskopf, GE Simon, A Kalsekar, C Nimsch, E Dunayevich, ... Depression and Anxiety 26 (1), 83-97, 2009 | 114 | 2009 |
Effect of combined naltrexone and bupropion therapy on the brain’s reactivity to food cues GJ Wang, D Tomasi, ND Volkow, R Wang, F Telang, EC Caparelli, ... International journal of obesity 38 (5), 682-688, 2014 | 86 | 2014 |
Affective state dependence of the Tridimensional Personality Questionnaire SM Strakowski, E Dunayevich, PE Keck Jr, SL McElroy Psychiatry Research 57 (3), 209-214, 1995 | 79 | 1995 |
Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation SR Marder, S Sorsaburu, E Dunayevich, JL Karagianis, IC Dawe, DM Falk, ... The Journal of clinical psychiatry 71 (4), 2392, 2010 | 67 | 2010 |
Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder … E Dunayevich, H Ascher-Svanum, F Zhao, JG Jacobson, GA Phillips, ... Journal of Clinical Psychiatry 68 (8), 1163-1171, 2007 | 67 | 2007 |